Seres Therapeutics, Inc. (MCRB) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) from a buy rating to a hold rating in a report released on Tuesday, August 8th.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other brokerages also recently issued reports on MCRB. BidaskClub upgraded shares of Seres Therapeutics from a hold rating to a buy rating in a research note on Tuesday, July 25th. ValuEngine upgraded shares of Seres Therapeutics from a sell rating to a hold rating in a research report on Tuesday, August 1st. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the stock a buy rating in a research report on Thursday, August 3rd. HC Wainwright restated a buy rating and set a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th. Finally, Cantor Fitzgerald set a $16.00 price target on shares of Seres Therapeutics and gave the company a buy rating in a research report on Thursday, May 4th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $17.00.

Seres Therapeutics (MCRB) traded down 2.93% during midday trading on Tuesday, hitting $12.94. The company’s stock had a trading volume of 160,677 shares. The company’s 50 day moving average price is $12.77 and its 200 day moving average price is $10.81. The firm’s market cap is $524.23 million. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $15.09.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.10. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The business had revenue of $3 million during the quarter, compared to analyst estimates of $3 million. During the same quarter last year, the firm posted ($0.70) EPS. The company’s revenue for the quarter was up .0% on a year-over-year basis. Analysts expect that Seres Therapeutics will post ($2.48) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/seres-therapeutics-inc-mcrb-lowered-to-hold-at-zacks-investment-research-updated.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Parametric Portfolio Associates LLC increased its stake in Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after buying an additional 279 shares during the period. California State Teachers Retirement System increased its stake in Seres Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock worth $410,000 after buying an additional 400 shares during the period. Teachers Advisors LLC increased its stake in Seres Therapeutics by 1.2% in the second quarter. Teachers Advisors LLC now owns 38,758 shares of the biotechnology company’s stock worth $438,000 after buying an additional 450 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Seres Therapeutics by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 494 shares during the period. Finally, American International Group Inc. increased its stake in Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after buying an additional 727 shares during the period. Institutional investors and hedge funds own 75.28% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply